Top

Quality of Life Research

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in:

22-01-2022

The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States

Auteurs: Marwan Alrasheed, Jeff Jianfei Guo, Alex C. Lin, Patricia R. Wigle, Angelica Hardee, Ana L. Hincapie

Gepubliceerd in: Quality of Life Research | Uitgave 8/2022

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is a significant epidemiological problem with rising prevalence. Due to limited literature, the objective of this study is to examine the association between polypharmacy and health-related quality of life (QoL) in NAFLD adult patients.

Methods

A retrospective observational study design was conducted to analyze health data collected by Steatohepatitis Clinical Research Network (NASH CRN). Patients were classified as receiving a polypharmacy therapy with five or more medications in their first screening visit. QoL was measured using the Short Form 36 (SF-36) instrument. Each patient self-reported the SF-36 form during the screening visit was compared between polypharmacy and non-polypharmacy groups using Wilcoxon Rank Sum test. Multivariable generalized linear models and multinomial logistic regression were performed to examine each predictor and its effect on QoL.

Results

Data included 1067 NAFLD adult patients; 834 patients used polypharmacy. The mean age was 48.64 years, and most patients were female (62%). Comparing NAFLD patients without steatohepatitis, borderline NASH, and definite NASH, the non-polypharmacy group had a significantly higher QoL than the polypharmacy group in Physical Component Summary (PCS) (86.25 vs 66.88, 85 vs 67.5, and 79.375 vs 63.12, respectively, all p < 0.01) and Mental Component Summary (MCS) (83.5 vs 73.38, 78.75 vs 67.62, and 78.75 vs 70.65, respectively, all p < 0.01).

Discussion and conclusion

Adults with NAFLD and polypharmacy have lower QoL than adults with NAFLD and non-polypharmacy. Number of medications had a significant negative impact on PCS, MCS, and all SF-36 domains except mental health, role physical limitation and role emotional limitation domains. Other factors that affect QoL negatively in NAFLD adult patients are female gender, obesity, diabetes, depression, and unemployment. Higher income had favorable effect on QoL.

vorige artikel The 5-year outcome of subjective quality of life in older schizophrenia patients

volgende artikel Illness cognitions and health-related quality of life in liver transplant patients related to length of stay, comorbidities and complications

Alleen toegankelijk voor geautoriseerde gebruikers

Ludwig, J., Viggiano, T. R., McGill, D. B., & Oh, B. J. (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings, 55(7), 434–438. PubMed

Definition & Facts of NAFLD & NASH | NIDDK [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved January 29, 2021, from https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., et al. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328–357. PubMedCrossRef

Cholankeril, G., Wong, R. J., Hu, M., Perumpail, R. B., Yoo, E. R., Puri, P., et al. (2017). Liver Transplantation for nonalcoholic steatohepatitis in the US: Temporal trends and outcomes. Digestive Diseases and Sciences, 62(10), 2915–2922. PubMedCrossRef

Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., et al. (2015). Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology, 148(3), 547–555. PubMedCrossRef

Younossi, Z. M., Stepanova, M., Younossi, Y., Golabi, P., Mishra, A., Rafiq, N., et al. (2020). Epidemiology of chronic liver diseases in the USA in the past three decades. Gut, 69(3), 564–568. PubMedCrossRef

Vernon, G., Baranova, A., & Younossi, Z. M. (2011). Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics, 34(3), 274–285. CrossRef

Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., et al. (2011). Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology, 140(1), 124–131. PubMedCrossRef

Bang, K. B., & Cho, Y. K. (2015). Comorbidities and metabolic derangement of NAFLD. Journal of Lifestyle Medicine, 5(1), 7–13. PubMedPubMedCentralCrossRef

10.

Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., et al. (2005). The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology, 129(1), 113–121. PubMedCrossRef

11.

Younossi, Z., & Henry, L. (2016). Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology, 150(8), 1778–1785. PubMedCrossRef

12.

Mohamad, B., Shah, V., Onyshchenko, M., Elshamy, M., Aucejo, F., Lopez, R., et al. (2016). Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatology International, 10(4), 632–639. PubMedCrossRef

13.

Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017). What is polypharmacy? A systematic review of definitions. BMC Geriatrics, 17(1), 230. PubMedPubMedCentralCrossRef

14.

Bakaki, P. M., Horace, A., Dawson, N., Winterstein, A., Waldron, J., Staley, J., et al. (2018). Defining pediatric polypharmacy: A scoping review. PLoS ONE, 13(11), e0208047. PubMedPubMedCentralCrossRef

15.

Gu, Q., Dillon, C. F., & Burt, V. L. (2010). Prescription drug use continues to increase: U.S. Prescription Drug Data for 2007–2008: (665492010–001). American Psychological Association. https://doi.org/10.1037/e665492010-001 CrossRef

16.

Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. (2015). Trends in prescription drug use among adults in the United States From 1999–2012. JAMA, 314(17), 1818. PubMedPubMedCentralCrossRef

17.

HRQOL Concepts | CDC [Internet]. (2018). Retrieved February 9, 2021, from https://www.cdc.gov/hrqol/concept.htm

18.

Monica 1776 Main Street Santa, California 90401–3208. 36-Item Short Form Survey from the RAND Medical Outcomes Study [Internet]. Retrieved February 1, 2021, from https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form.html

19.

Ware, J. E., & Gandek, B. (1998). Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. Journal of Clinical Epidemiology, 51(11), 903–912. PubMedCrossRef

20.

Dan, A. A., Kallman, J. B., Wheeler, A., Younoszai, Z., Collantes, R., Bondini, S., et al. (2007). Health-related quality of life in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 26(6), 815–820. CrossRef

21.

Assimakopoulos, K., Karaivazoglou, K., Tsermpini, E.-E., Diamantopoulou, G., & Triantos, C. (2018). Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. Journal of Psychosomatic Research, 112, 73–80. PubMedCrossRef

22.

Sayiner, M., Stepanova, M., Pham, H., Noor, B., Walters, M., & Younossi, Z. M. (2016). Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenteroligy, 3(1), e000106. CrossRef

23.

Chawla, K. S., Talwalkar, J. A., Keach, J. C., Malinchoc, M., Lindor, K. D., & Jorgensen, R. (2016). Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH). BMJ Open Gastroenterology, 3(1), e000069. PubMedPubMedCentralCrossRef

24.

Patel, P. J., Hayward, K. L., Rudra, R., Horsfall, L. U., Hossain, F., Williams, S., et al. (2017). Multimorbidity and polypharmacy in diabetic patients with NAFLD. Medicine (Baltimore), 96, e6761. CrossRef

25.

Spengler, E. K., & Loomba, R. (2015). Recommendations for diagnosis, referral for liver biopsy, and treatment of NAFLD and NASH. Mayo Clinic Proceedings, 90(9), 1233–1246. PubMedCrossRef

26.

Babcock, Z. R., Kogut, S. J., & Vyas, A. (2020). Association between polypharmacy and health-related quality of life among cancer survivors in the United States. Journal of Cancer Survivorship, 14(1), 89–99. PubMedCrossRef

27.

Schenker, Y., Park, S. Y., Jeong, K., Pruskowski, J., Kavalieratos, D., Resick, J., et al. (2019). Associations between polypharmacy, symptom burden, and quality of life in patients with advanced, life-limiting illness. Journal of General Internal Medicine, 34(4), 559–566. PubMedPubMedCentralCrossRef

28.

Okoli, C., de los Rios, P., Eremin, A., Brough, G., Young, B., & Short, D. (2020). Relationship between polypharmacy and quality of life among people in 24 Countries living with HIV. Preventing Chronic Disease, 17, 190359. CrossRef

29.

(2003). Nonalcoholic steatohepatitis clinical research network. Hepatology 37(2):244

30.

Monica 1776 Main Street Santa, California 90401–3208. 36-Item Short Form Survey (SF-36) Scoring Instructions [Internet]. Retrieved September 6, 2021, from https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html

31.

Standard_Operating_Procedures.pdf [Internet]. Retrieved December 13, 2021 from https://repository.niddk.nih.gov/media/studies/nafld_adult/Standard_Operating_Procedures.pdf

32.

Woźniak, I., Kolonko, A., Chudek, J., Nowak, Ł, Farnik, M., & Więcek, A. (2018). Influence of polypharmacy on the quality of life in stable kidney transplant recipients. Transplantation Proceedings, 50(6), 1896–1899. PubMedCrossRef

33.

Alexander, H. B., Broshek, D. K., & Quigg, M. (2018). Quality of life in adults with epilepsy is associated with anticonvulsant polypharmacy independent of seizure status. Epilepsy & Behavior, 78, 96–99. CrossRef

34.

Vyas, A., Kang, F., & Barbour, M. (2020). Association between polypharmacy and health-related quality of life among US adults with cardiometabolic risk factors. Quality of Life Research, 29(4), 977–986. PubMedCrossRef

35.

Golabi, P., Otgonsuren, M., Cable, R., Felix, S., Koenig, A., Sayiner, M., et al. (2016). Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health and Quality of Life Outcomes, 14, 18. PubMedPubMedCentralCrossRef

36.

Kennedy-Martin, T., Bae, J. P., Paczkowski, R., & Freeman, E. (2017). Health-related quality of life burden of nonalcoholic steatohepatitis: A robust pragmatic literature review. Journal of Patient-Reported Outcomes, 2, 28. PubMedCrossRef

37.

Bezemer, G., Van Gool, A. R., Verheij-Hart, E., Hansen, B. E., Lurie, Y., Esteban, J. I., et al. (2012). Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterology, 12(1), 11. PubMedPubMedCentralCrossRef

38.

Huber, Y., Boyle, M., Hallsworth, K., Tiniakos, D., Straub, B. K., Labenz, C., et al. (2019). Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clinical Gastroenterology and Hepatology, 17(10), 2085-2092.e1. PubMedCrossRef

39.

David, K., Kowdley, K. V., Unalp, A., Kanwal, F., Brunt, E. M., & Schwimmer, J. B. (2009). Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology, 49(6), 1904–1912. PubMedCrossRef

40.

Alrasheed, M., Alsuhibani, A., Hincapie, A. L., Welge, J. (2021) Comparison of quality of life between men and women with chronic liver diseases using chronic liver disease questionnaire (CLDQ): A meta-analysis. In Pharmacoepidemiology and Drug Safety 2021 Aug 1 (Vol. 30, pp. 181–181). 111 RIVER ST, HOBOKEN 07030–5774, NJ USA: WILEY.

41.

Younossi, Z. M., Stepanova, M., Sulkowski, M., Naggie, S., Henry, L., & Hunt, S. (2016). Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. Journal of Viral Hepatitis, 23(11), 857–865. PubMedCrossRef

42.

Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., et al. (2017). Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology (Baltimore, MD), 65(5), 1557–1565. CrossRef

43.

Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., et al. (2017). Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology, 67(6), 1265–1273. PubMedCrossRef

44.

Choi, J. M., Chung, G. E., Kang, S. J., Kwak, M.-S., Yang, J. I., Park, B., et al. (2021). Association between anxiety and depression and nonalcoholic fatty liver disease. Frontiers in Medicine, 7, 1068. CrossRef

45.

Elliott, T. E., Renier, C. M., & Palcher, J. A. (2003). Chronic pain, depression, and quality of life: Correlations and predictive value of the SF-36. Chronic Pain, 4, 331.

46.

McKee-Ryan, F., Song, Z., Wanberg, C. R., & Kinicki, A. J. (2005). Psychological and physical well-being during unemployment: A meta-analytic study. Journal of Applied Psychology, 90(1), 53. PubMedCrossRef

47.

Paul, K. I., & Moser, K. (2009). Unemployment impairs mental health: Meta-analyses. Journal of Vocational Behavior, 74(3), 264–282. CrossRef

48.

Bartley, M. (1994). Unemployment and ill health: Understanding the relationship. Journal of Epidemiology and Community Health, 48(4), 333–337. PubMedPubMedCentralCrossRef

49.

Rodriguez, E. (2001). Keeping the unemployed healthy: The effect of means-tested and entitlement benefits in Britain, Germany, and the United States. American Journal of Public Health, 91(9), 1403–1411. PubMedPubMedCentralCrossRef

50.

Artazcoz, L., Benach, J., Borrell, C., & Cortes, I. (2004). Unemployment and mental health: Understanding the interactions among gender, family roles, and social class. American Journal of Public Health. https://doi.org/10.2105/AJPH.94.1.82 CrossRefPubMedPubMedCentral

51.

Bunevicius, A. (2017). Reliability and validity of the SF-36 Health Survey Questionnaire in patients with brain tumors: A cross-sectional study. Health and Quality of Life Outcomes, 15, 92. PubMedPubMedCentralCrossRef

52.

Brazier, J. E., Harper, R., Jones, N. M., O’Cathain, A., Thomas, K. J., Usherwood, T., et al. (1992). Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ, 305(6846), 160–164. PubMedPubMedCentralCrossRef

53.

Failde, I., & Ramos, I. (2000). Validity and reliability of the SF-36 Health Survey Questionnaire in patients with coronary artery disease. Journal of Clinical Epidemiology, 53(4), 359–365. PubMedCrossRef

54.

McHorney, C. A., Ware, J. E., Lu, J. F. R., & Sherbourne, C. D. (1994). The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32(1), 40–66. PubMedCrossRef

55.

Posthouwer, D., Plug, I., van der Bom, J. G., Fischer, K., Rosendaal, F. R., & Mauser-Bunschoten, E. P. (2005). Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica, 90(6), 846–850. PubMed

Titel: The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States
Auteurs: Marwan Alrasheed
Jeff Jianfei Guo
Alex C. Lin
Patricia R. Wigle
Angelica Hardee
Ana L. Hincapie
Publicatiedatum: 22-01-2022
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 8/2022
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-022-03090-6

Bohn Stafleu van Loghum

Tip

Swipe om te navigeren naar een ander artikel

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Background

Methods

Results

Discussion and conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 8/2022

Illness cognitions and health-related quality of life in liver transplant patients related to length of stay, comorbidities and complications

Patient-reported outcome measures to evaluate postoperative quality of life in patients undergoing elective abdominal surgery: a systematic review

Health-related quality of life among patients with gallstone disease: a systematic review and meta-analysis of EQ-5D utility scores

A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing

Correction to: Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions

Active and sham transcranial direct current stimulation (tDCS) improved quality of life in female patients with fibromyalgia